Collectively, these data clearly indicated that treatment with EPO after the establishment of obesity-related T2D significantly reduced the body weights, corrected hyperglycemia and glucose intolerance, and mitigated the HFD-induced hyperinsulinemia in HFD-fed mice. The gene discussed is EPO; the disease is Hyperglycemia.